Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
BIIB - Biogen Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$212.00
DETAILS
HIGH:
$260.00
LOW:
$143.00
MEDIAN:
$222.00
CONSENSUS:
$212.00
UPSIDE:
9.41%
Stock News
Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky
Biogen shares dropped approximately 6.4% in a single session after Phase 2 CELIA trial data for diranersen missed its primary endpoint -- wiping out billions in market value. NEW YORK, May 22, 2026 /PRNewswire/ -- Biogen Inc. (NASDAQ: BIIB) investors lost approximately 6.4% per share on May 14, 2026, when the company disclosed that its Phase 2 "CELIA" trial for diranersen (BIIB080) failed to meet its primary dose-response endpoint in early Alzheimer's disease.
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
U.S. Food & Drug Administration (FDA) events crystallize the risk/reward thesis for many biotechnology stocks, and Biogen Inc.'s NASDAQ: BIIB latest Alzheimer's update shows why that trade can turn quickly.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study
Biogen and Denali Therapeutics said on Thursday they will discontinue development of their Parkinson's drug after it failed to meet the main goal in a mid-to-late stage study.
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), an investigational small molecule inhibitor of LRRK2 (leucine-rich repeat kinase 2), in individuals with early-stage Parkinson's disease. Results from the study show that BIIB122 did not slow the progression of Parkinson's disease versus placebo, as measured by the primary endpoint of Time to Confirmed Worsening in the modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II and III combined score. Secondary endpoints also did not show a benefit with BIIB122. Exploratory biomarker endpoints demonstrated >90% kinase inhibition of peripheral LRRK2 (phosphoserine 935) and, in a cerebrospinal fluid (CSF) sub-study, up to approximately 30% reduction observed in a biomarker of LRRK2 activity (phosphorylated Rab10). Expected levels of BIIB122 in the blood and CSF were sustained across the study. BIIB122 was generally well tolerated with an acceptable safety profile. Based on these results, Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson's disease. Denali will continue to independently conduct the Phase 2a BEACON study evaluating the small molecule inhibitor in carriers of a pathogenic LRRK2 variant.
Levi & Korsinsky Announces Investigation of Securities Claims Against Biogen Inc. (BIIB)
Biogen stock fell approximately 6.4% in a single session after Phase 2 "CELIA" trial data for diranersen failed to meet its primary endpoint. NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) shares dropped approximately 6.4% on May 14, 2026, after the company released mixed Phase 2 "CELIA" topline data for its Alzheimer's candidate diranersen (BIIB080), with the trial failing to meet its primary dose-response endpoint.
BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud
NEW YORK--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) shareholders lost approximately 6.4% of their investment value on May 14, 2026, when the company disclosed that its Phase 2 "CELIA" trial for Alzheimer's candidate diranersen (BIIB080) failed to meet its primary dose-response endpoint. Investors who lost money on BIIB are encouraged to submit their information for a free evaluation. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-75.
BIIB ALERT: Levi & Korsinsky Investigates Biogen Inc. for Possible Securities Fraud Violations
New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Biogen Inc. ("Biogen Inc.") (NASDAQ:BIIB) concerning potential violations of the federal securities laws. The stock fell sharply on heavy volume following the May 14 topline data release.
BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations
Biogen Phase 2 CELIA trial data sent shares down 6.4% after it was revealed that topline data missed its primary endpoint. NEW YORK, May 18, 2026 /PRNewswire/ -- Biogen Inc. (NASDAQ: BIIB) shareholders lost 6.4% per share on May 14, 2026, when Phase 2 "CELIA" topline data for diranersen missed its primary dose-response endpoint.
Biogen Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Biogen Inc. (BIIB)
Biogen shares dropped 6.4% after Phase 2 CELIA trial data revealed information absent from the Company's filings. NEW YORK, May 15, 2026 /PRNewswire/ -- Biogen Inc. (NASDAQ: BIIB) investors lost approximately 6.4% per share on May 14, 2026, after Phase 2 "CELIA" topline data for diranersen missed its primary dose-response endpoint.
Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny - Contact Levi & Korsinsky for Details
New York, New York--(Newsfile Corp. - May 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Biogen Inc. ("Biogen Inc.") (NASDAQ: BIIB) concerning potential violations of the federal securities laws. The stock fell sharply on heavy volume following the May 14 topline data release.
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.
Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity
Biogen Inc. is upgraded from Sell to Hold, reflecting recent strategic moves and a modest rebound despite persistent structural challenges. BIIB's acquisition of Apellis for ~$5.6bn adds near-term revenue and nephrology expansion, though realizing a robust kidney franchise remains uncertain. Q1 results were mixed: MS revenues are stable, but long-term decline looms, while new product launches are unlikely before 2028/2029.
Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push
Biogen NASDAQ: BIIB is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company's next phase of growth, Adam Meyers, head of the company's immunology and new disease areas franchise, said at Bank of America's annual healthcare conference in Las Vegas.
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
Biogen plans to advance an experimental drug for Alzheimer's disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen plans to move it into Phase 3 testing because of signals suggesting the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.
Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway.
Biogen's diranersen showed ‘robust reductions' in key biomarkers during a Phase 2 trial, the biotech said.
Biogen Completes Acquisition of Apellis Pharmaceuticals
CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, complement-driven diseases, is now a wholly owned subsidiary of Biogen.
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study evaluating diranersen (IONIS-MAPTRx/BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease (AD). The CELIA results provide the first evidence from a randomized Phase 2 study of a tau-directed therapy demonstrating both robust biomarker impac.
Biogen's Alzheimer's drug fails to meet mid-stage trial goal
Biogen said on Thursday its Alzheimer's drug did not meet the main goal of a mid-stage trial.
Price Targets
Biogen price target raised to $225 from $214 at Piper Sandler
$225.00
(was $191.37)
Piper Sandler
Biogen price target raised to $206 from $200 at Morgan Stanley
$206.00
(was $188.76)
Morgan Stanley
Biogen price target raised to $222 from $213 at RBC Capital
$222.00
(was $190.78)
Brian Abrahams
·
RBC Capital
Biogen price target raised to $196 from $191 at Wedbush
$196.00
(was $194.38)
Wedbush
Biogen price target raised to $260 from $246 at Guggenheim
$260.00
(was $194.38)
Guggenheim
Biogen upgraded to Overweight from Equal Weight at Wells Fargo
$250.00
(was $177.35)
Mohit Bansal
·
Wells Fargo
Biogen upgraded to Overweight from Neutral at Piper Sandler
$214.00
(was $176.37)
Piper Sandler
Biogen price target raised to $200 from $190 at Morgan Stanley
$200.00
(was $173.48)
Morgan Stanley
Biogen initiated with an Equal Weight at Barclays
$185.00
(was $192.08)
Emily Field
·
Barclays
Biogen price target raised to $236 from $207 at Mizuho
$236.00
(was $188.99)
Mizuho Securities
Biogen price target raised to $187 from $178 at Wedbush
$187.00
(was $192.72)
Laura Chico
·
Wedbush
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)
$231.00
(was $196.00)
Wolfe Research
Biogen price target raised to $233 from $217 at RBC Capital
$233.00
(was $195.93)
RBC Capital
Biogen (BIIB) PT Raised to $215 at TD Cowen
$215.00
(was $195.45)
Wolfe Research
Biogen price target raised to $193 from $190 at Truist
$193.00
(was $201.18)
Danielle Brill
·
Truist Financial
Biogen price target raised to $230 from $220 at Canaccord
$230.00
(was $201.18)
Canaccord Genuity
Biogen price target raised to $177 from $157 at Piper Sandler
$177.00
(was $201.18)
Piper Sandler
Biogen price target raised to $246 from $185 at Guggenheim
$246.00
(was $201.18)
Yatin Suneja
·
Guggenheim
Biogen price target raised to $201 from $191 at Bernstein
$201.00
(was $201.18)
William Pickering
·
Tudor Pickering
Biogen price target raised to $228 from $194 at H.C. Wainwright
$228.00
(was $201.18)
Andrew Fein
·
H.C. Wainwright